EMA Authorised: Litak (cladribine) — Lipomed GmbH

View source ↗

Summary

The European Medicines Agency authorized Litak, a cladribine product from Lipomed GmbH, for hairy cell leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Litak (cladribine)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Hairy Cell. MAH: Lipomed GmbH. Decision date: 19/12/2024